Disease | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
Neoplasms
|
0.710 | GeneticVariation | CLINVAR | An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. | 17483355 | 2007 | |||||
Neoplasms
|
0.710 | GeneticVariation | BEFREE | By this approach, Met Y1253D was detected in tumours of 15 out of 13</span>8 patients (10.9%). | 14627992 | 2003 | |||||
Carcinoma
|
0.700 | GeneticVariation | CLINVAR | Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. | 12460923 | 2002 | |||||
Neoplasm Metastasis
|
0.020 | GeneticVariation | BEFREE | Distant metastasis-free survival (P = 0.008) was associated with MET Y1253D. | 19639388 | 2009 | |||||
Neoplasm Metastasis
|
0.020 | GeneticVariation | BEFREE | The Y1235D mutation identified in metastases was shown to induce constitutive activation and a motile-invasive phenotype on transduced carcinoma cells. | 16245927 | 2005 | |||||
Squamous cell carcinoma of the head and neck
|
0.010 | GeneticVariation | BEFREE | The observed association between MET Y1253D-activating point mutation and decreased distant metastasis-free survival in advanced HNSCC suggests that MET may be a potential target for specific treatment interventions. | 19639388 | 2009 | |||||
Secondary Neoplasm
|
0.010 | GeneticVariation | BEFREE | The Y1235D mutation identified in metastases was shown to induce constitutive activation and a motile-invasive phenotype on transduced carcinoma cells. | 16245927 | 2005 | |||||
Oropharyngeal Carcinoma
|
0.010 | GeneticVariation | BEFREE | Our results provide evidence that the Met-activating mutation Y1253D is present in a notable subset of patients with oropharyngeal cancer and indicate that it may interfere with radioresponsiveness of these tumours, supporting the notion of aberrant Met signalling as a potential target for radiosensitization. | 14627992 | 2003 | |||||
Malignant Squamous Cell Neoplasm
|
0.010 | GeneticVariation | BEFREE | We determined the prevalence and clinical impact of the Met-activating mutation Y1253D in patients with squamous cell cancer of the oropharynx treated by radical radiotherapy. | 14627992 | 2003 | |||||
Malignant neoplasm of oropharynx
|
0.010 | GeneticVariation | BEFREE | Our results provide evidence that the Met-activating mutation Y1253D is present in a notable subset of patients with oropharyngeal cancer and indicate that it may interfere with radioresponsiveness of these tumours, supporting the notion of aberrant Met signalling as a potential target for radiosensitization. | 14627992 | 2003 | |||||
Oropharynx (excludes nasopharynx)
|
0.010 | GeneticVariation | BEFREE | We determined the prevalence and clinical impact of the Met-activating mutation Y1253D in patients with squamous cell cancer of the oropharynx treated by radical radiotherapy. | 14627992 | 2003 | |||||
Squamous cell carcinoma
|
0.010 | GeneticVariation | BEFREE | We determined the prevalence and clinical impact of the Met-activating mutation Y1253D in patients with squamous cell cancer of the oropharynx treated by radical radiotherapy. | 14627992 | 2003 |